title: Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history.
abstract: BACKGROUND
  Fibroblast growth factor 19 (FGF19) and FGF21 are considered to be novel adipokines that improve glucose tolerance and insulin sensitivity. In the current study, we investigated serum FGF19 and FGF21 levels in patients with gestational diabetes mellitus (GDM) and explored their relationships with anthropometric and endocrine parameters.
  
  
  METHODS
  Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in patients with GDM (n = 30) and healthy pregnant controls (n = 60) matched for maternal and gestational age. Serum FGF19 and FGF21 levels were correlated with anthropometric, metabolic, and endocrine parameters.
  
  
  RESULTS
  Circulating levels of FGF19 were significantly reduced in patients with GDM relative to healthy pregnant subjects, whereas FGF21 levels were increased in GDM patients. Serum FGF19 levels independently and inversely correlated with insulin resistance (increased homeostasis model assessment of insulin resistance, HOMA-IR) and were positively related to serum adiponectin in both groups. In contrast, serum FGF21 levels independently and positively correlated with insulin resistance and serum triglycerides and were inversely related to serum adiponectin. In addition, in the combined population of both groups, those women with preconception polycystic ovary syndrome (PCOS) history had the lowest levels of FGF19, which were significantly lower than those in GDM patients without PCOS history and those in controls without PCOS history.
  
  
  CONCLUSIONS
  Circulating FGF19 levels are reduced in GDM patients, in contrast with FGF21 levels. Both serum FGF19 and FGF21 levels are strongly related to insulin resistance and serum levels of adiponectin. Considering the different situation between FGF19 and FGF21, we suggest that reduced serum FGF19 levels could be involved in the pathophysiology of GDM, while increased serum FGF21 levels could be in a compensatory response to this disease.
authors.affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
authors.forename: Dongyu
authors.initials: D
authors.lastname: Wang
authors.forename: Wenjing
authors.initials: W
authors.lastname: Zhu
authors.forename: Jieming
authors.initials: J
authors.lastname: Li
authors.forename: Chongyou
authors.initials: C
authors.lastname: An
authors.forename: Zilian
authors.initials: Z
authors.lastname: Wang
mesh_terms: D052242:Adiponectin / Q000097:blood* / Q000235:genetics; D000328:Adult; D016022:Case-Control Studies; D048909:Diabetes Complications / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D016640:Diabetes, Gestational / Q000097:blood* / Q000503:physiopathology; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood* / Q000235:genetics; D015870:Gene Expression; D005865:Gestational Age; D006801:Humans; D007328:Insulin / Q000097:blood / Q000235:genetics; D007333:Insulin Resistance; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D011247:Pregnancy; D014280:Triglycerides / Q000097:blood
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; C117476:FGF19 protein, human; D007328:Insulin; D014280:Triglycerides; C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors